SELLAS Life Sciences Group, Inc. (SLS): EBITDA

Operating income plus depreciation and amortization for the same annual period and currency, computed by TickerFacts from the filed figures. Not the company's adjusted EBITDA; a year without both inputs is left out.

Restated years: each year's figure is from the latest filing that reports it. The company later restated the years ended 2013-12-31, 2016-12-31 (for example after a spin-off or a discontinued operation), while the year before each was last reported on the old basis. Changes across those points are marked n/c (not comparable), and growth rates are not computed across them.

Older than the company's other figures. The latest EBITDA is for the year ended 2016-12-31, while the company's latest annual report covers the year ended 2025-12-31. Its later filings do not report Depreciation & Amortization, which EBITDA is computed from, under the concepts TickerFacts maps.

-$15.98M
Year ended 2016-12-31
2011-12-31: -$12.32M2012-12-31: -$21.15M2013-12-31: -$28.20M2014-12-31: -$43.81M2015-12-31: -$34.11M2016-12-31: -$15.98M-$15.98M
2011-12-31 EBITDA (USD) 2016-12-31
Period endedEBITDAChange YoYSource filing
2016-12-31-$15.98Mn/c2018-04-13, From 2016-01-01
2015-12-31-$34.11Mn/m2017-03-15, From 2015-01-01
2014-12-31-$43.81Mn/m2017-03-15, From 2014-01-01
2013-12-31-$28.20Mn/c2016-04-15, From 2013-01-01
2012-12-31-$21.15Mn/m2015-03-05, From 2012-01-01
2011-12-31-$12.32Mn/a2014-03-17, From 2011-01-01